RAPIVAB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rapivab, and what generic alternatives are available?
Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.
This drug has seventy patent family members in twenty-eight countries.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.
DrugPatentWatch® Generic Entry Outlook for Rapivab
Rapivab was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 16, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for RAPIVAB
International Patents: | 70 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 3 |
Patent Applications: | 1,133 |
Drug Prices: | Drug price information for RAPIVAB |
What excipients (inactive ingredients) are in RAPIVAB? | RAPIVAB excipients list |
DailyMed Link: | RAPIVAB at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RAPIVAB
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Oxford | Phase 2 |
BioCryst Pharmaceuticals | Phase 3 |
Johns Hopkins University | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for RAPIVAB
US Patents and Regulatory Information for RAPIVAB
RAPIVAB is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RAPIVAB is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RAPIVAB
Antiviral treatments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Antiviral treatments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Antiviral treatments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Antiviral treatments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
Antiviral treatments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RAPIVAB
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for RAPIVAB
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Biocryst | Alpivab | peramivir | EMEA/H/C/004299 Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. |
Withdrawn | no | no | no | 2018-04-13 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RAPIVAB
See the table below for patents covering RAPIVAB around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 2020002008 | TRATAMIENTOS ANTIVIRALES INTRAVENOSOS. (INTRAVENOUS ANTIVIRAL TREATMENTS.) | ⤷ Try a Trial |
Poland | 341431 | ⤷ Try a Trial | |
Japan | 5709688 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2007117241 | ⤷ Try a Trial | |
Brazil | 9813480 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |